BMI View: The gradual easing of sanctions in Iran will lead to an uptick in interest from multinational pharmaceutical companies, many of which chose not to do business in Iran during this time. The supply of high value patented medicines will still be satisfied by multinationals despite increasing competition from domestic companies, with the easing of sanctions providing a more attractive operating environment.